To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile MDM2 amp
Therapy Milademetan
Indication/Tumor Type dedifferentiated liposarcoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MDM2 amp dedifferentiated liposarcoma sensitive Milademetan Phase I Actionable In a Phase I trial, Milademetan treatment resulted in an objective response rate of 3.8% (2/53, 2 partial responses), a disease control rate of 58.5%, and a median progression-free survival of 7.2 months in patients with dedifferentiated liposarcoma, 100% (22/22) of the patients tested for MDM2 had MDM2 amplification (CN > 6) with a median CN of 28.6 (PMID: 36669146; NCT01877382). 36669146
PubMed Id Reference Title Details
(36669146) A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Full reference...